PMID: 9447236Feb 3, 1998Paper

Mutation of D. radiodurans in a gene homologous to ruvB of E. coli

Mutation Research
S KitayamaH Itoh

Abstract

Following the digestion of chromosomal DNA of Deinococcus radiodurans with a restriction enzyme a partial genomic library was constructed using lambda phage as a vector. A phage clone whose DNA can complement the deficiency in a radiation-sensitive mutant of D. radiodurans was isolated. Following the subcloning using phasmid vector, a hybrid plasmid containing 1.2 kb inserted DNA was obtained. After the determination of nucleotide sequence, the deduced amino acid sequence showed close homology to RuvB protein of Escherichia coli; approximately 81% of the amino acids (310 residues in total) was homologous (152 were identical and 100 amino acids were similar). The putative protein has a conserved ATP binding domain characteristic of DNA helicases. However, we could not find an SOS promoter and ORF for RuvA protein in the sequence upstream of ruvB in contrast to the E. coli homologue. The mutant was transformed with exogenous DNA at the same rate as the wild-type cells, but it was moderately sensitive to UV, gamma-rays and to interstrand cross-linking reagents.

References

Nov 8, 1968·Biochemical and Biophysical Research Communications·S Kitayama, A Matsuyama
Sep 1, 1983·Journal of Bacteriology·S KitayamaK Totsuka
Jun 30, 1982·Biochimica Et Biophysica Acta·S Kitayama
Sep 1, 1981·Journal of Biochemistry· HarsojoA Matsuyama
Oct 11, 1994·Proceedings of the National Academy of Sciences of the United States of America·D E AdamsS C West

❮ Previous
Next ❯

Citations

Oct 13, 2011·Molecular & Cellular Proteomics : MCP·Bhakti Basu, Shree Kumar Apte
Jan 29, 2008·Journal of Bacteriology·Guangzhi XuYuejin Hua
Mar 5, 2011·Microbiology and Molecular Biology Reviews : MMBR·Dea Slade, Miroslav Radman
Jun 24, 2008·Critical Reviews in Biochemistry and Molecular Biology·Melanie BlasiusUlrich Hübscher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.